Geraldine Henwood - 20 Apr 2021 Form 4/A - Amendment Insider Report for Recro Pharma, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 20 Apr 2021
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 17 May 2021, 16:04:40 UTC
Original report date: 22 Apr 2021
Next SEC filing: 10 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Ryan D. Lake, attorney-in-fact

Key filing fact

Geraldine Henwood filed Form 4/A - Amendment for Recro Pharma, Inc. on 17 May 2021.

Key facts

This page summarizes Geraldine Henwood's Form 4/A - Amendment filing for Recro Pharma, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 May 2021, 16:04.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +38,012
Change %
Price: $0.000000
Shares after: 38,012
Date: 20 Apr 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,012
Exercise price: $2.60
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amended Form 4 is being filed to correct a typographical error in the exercise price of the stock options acquired on April 20, 2021 as reported on the Form 4 filed on April 22, 2021.

Footnote F2

The stock option will vest on April 20, 2022.